🆚 Keitaro vs. LeadsRx
- 📈 Keitaro is twice as popular as LeadsRx.
- 🌍 Keitaro is more popular in Russia, the United Kingdom, and the Netherlands.
- 🌎 LeadsRx is more popular in the United States, Canada, and Australia.
KeitaroType
About
Keitaro is a self-hosted ad tracking platform that enables affiliate marketers and media buyers to track, route, and optimize traffic across advertising campaigns.
It features a real-time click-processing engine, customizable redirect flows, smart traffic distribution based on conversions and user attributes, bot and proxy filtering, and landing page and offer rotation.
LeadsRx is a cross-channel marketing and attribution platform that provides multi-touch attribution, customizable attribution windows and actionable insights.
Headquarters
Pricing
(1 user, 1 domain) €49/month
(1 user, 100 domains) €89/month
(5 users, 500 domains) €129/month
(50 users, 5,000 domains) €200/month
(unlimited users and domains) €400/month
Categories
Popularity
Determined by the number of sites using each technology.
Market share
Popularity by country
Determined by the number of sites detected from each country.
Awards
- 🥉 Third most popular in Russia in the Marketing Attribution category.
- 🔥 16th most popular in Russia in the Analytics category.
- 🔥 14th most popular in the United States in the Marketing Attribution category.
- ⬆️ 104th most popular in the United States in the Analytics category.
Popularity by domain category
Determined by the number of sites in each category.
Top sites
Top-ranked sites that use these technologies.
Compare alternatives
Technologies with similar characteristics.
Unbounce company profile🗃️ About This Data
- We evaluate the popularity of technologies based on the number of websites where we detect their usage.
- Technologies without a detectable web footprint, and those we do not track, are not reflected in the calculated market share.
- This report is based on the analysis of 3,896,634 websites.
- Statistics were last calculated on .
- For more details, see our methodology and disclaimer.